NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): PR Newswire
  • Source:
    PR Newswire US. 06/22/2024.
  • Additional Information
    • Alternate Title:
      NEUROBO-PHARMA
    • Subject Terms:
      Massachusetts
    • Abstract:
      DA-1726 Also Exhibited Superior Glucose Lowering Compared to Survodutide [ABSTRACT FROM PUBLISHER]